Double-edged sword effect of anticoagulant in COVID-19 infection
Coagulation predominant-type coagulopathy such as microthrombosis and macrothrombosis is a well-known recognised complication found in COVID-19 infected critically ill patients. In the context of high incidence of thrombotic events in patients with COVID-19, supplementation with anticoagulant therap...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English English |
Published: |
BMJ Publishing Group
2021
|
Subjects: | |
Online Access: | https://eprints.ums.edu.my/id/eprint/30036/1/Double-edged%20sword%20effect%20of%20anticoagulant%20in%20COVID-19%20infection%20FULL%20TEXT.pdf https://eprints.ums.edu.my/id/eprint/30036/2/Double-edged%20sword%20effect%20of%20anticoagulant%20in%20COVID-19%20infection%20ABSTRACT.pdf https://eprints.ums.edu.my/id/eprint/30036/ https://casereports.bmj.com/content/bmjcr/14/3/e241955.full.pdf https://doi.org/10.1136/bcr-2021- 241955 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
my.ums.eprints.30036 |
---|---|
record_format |
eprints |
spelling |
my.ums.eprints.300362021-07-22T05:49:25Z https://eprints.ums.edu.my/id/eprint/30036/ Double-edged sword effect of anticoagulant in COVID-19 infection May Honey Ohn Jun Rong Ng Khin Maung Ohn Ng Pey Luen R Medicine (General) Coagulation predominant-type coagulopathy such as microthrombosis and macrothrombosis is a well-known recognised complication found in COVID-19 infected critically ill patients. In the context of high incidence of thrombotic events in patients with COVID-19, supplementation with anticoagulant therapy has been routinely recommended and shown to reduce mortality. However, the recommended type, dose, duration and timing of anticoagulant has not been determined yet. Spontaneous retroperitoneal haematoma secondary to anticoagulant therapy is one of the well-known but self-limiting conditions. We report a 51-year-old COVID-19 positive woman, who was taking intermediate-intensity heparin therapy for venous thromboembolism prophylaxis and died from complication of retroperitoneal bleeding. Further studies are needed to verify the risk–benefit ratio of anticoagulant therapy in patients with COVID-19. Although anticoagulant deems appropriate to use in patients with COVID-19, clinicians should be cautious about major bleeding complication such as retroperitoneal haemorrhage even when full therapeutic dosage is not used. BMJ Publishing Group 2021 Article PeerReviewed text en https://eprints.ums.edu.my/id/eprint/30036/1/Double-edged%20sword%20effect%20of%20anticoagulant%20in%20COVID-19%20infection%20FULL%20TEXT.pdf text en https://eprints.ums.edu.my/id/eprint/30036/2/Double-edged%20sword%20effect%20of%20anticoagulant%20in%20COVID-19%20infection%20ABSTRACT.pdf May Honey Ohn and Jun Rong Ng and Khin Maung Ohn and Ng Pey Luen (2021) Double-edged sword effect of anticoagulant in COVID-19 infection. BMJ Case Reports, 14 (3). pp. 1-4. ISSN 1757-790X (E-ISSN) https://casereports.bmj.com/content/bmjcr/14/3/e241955.full.pdf https://doi.org/10.1136/bcr-2021- 241955 |
institution |
Universiti Malaysia Sabah |
building |
UMS Library |
collection |
Institutional Repository |
continent |
Asia |
country |
Malaysia |
content_provider |
Universiti Malaysia Sabah |
content_source |
UMS Institutional Repository |
url_provider |
http://eprints.ums.edu.my/ |
language |
English English |
topic |
R Medicine (General) |
spellingShingle |
R Medicine (General) May Honey Ohn Jun Rong Ng Khin Maung Ohn Ng Pey Luen Double-edged sword effect of anticoagulant in COVID-19 infection |
description |
Coagulation predominant-type coagulopathy such as microthrombosis and macrothrombosis is a well-known recognised complication found in COVID-19 infected critically ill patients. In the context of high incidence of thrombotic events in patients with COVID-19, supplementation with anticoagulant therapy has been routinely recommended and shown to reduce mortality. However, the recommended type, dose, duration and timing of anticoagulant has not been determined yet. Spontaneous retroperitoneal haematoma secondary to anticoagulant therapy is one of the well-known but self-limiting conditions. We report a 51-year-old COVID-19 positive woman, who was taking intermediate-intensity heparin therapy for venous thromboembolism prophylaxis and died from complication of retroperitoneal bleeding. Further studies are needed to verify the risk–benefit ratio of anticoagulant therapy in patients with COVID-19. Although anticoagulant deems appropriate to use in patients with COVID-19, clinicians should be cautious about major bleeding complication such as retroperitoneal haemorrhage even when full therapeutic dosage is not used. |
format |
Article |
author |
May Honey Ohn Jun Rong Ng Khin Maung Ohn Ng Pey Luen |
author_facet |
May Honey Ohn Jun Rong Ng Khin Maung Ohn Ng Pey Luen |
author_sort |
May Honey Ohn |
title |
Double-edged sword effect of anticoagulant in COVID-19 infection |
title_short |
Double-edged sword effect of anticoagulant in COVID-19 infection |
title_full |
Double-edged sword effect of anticoagulant in COVID-19 infection |
title_fullStr |
Double-edged sword effect of anticoagulant in COVID-19 infection |
title_full_unstemmed |
Double-edged sword effect of anticoagulant in COVID-19 infection |
title_sort |
double-edged sword effect of anticoagulant in covid-19 infection |
publisher |
BMJ Publishing Group |
publishDate |
2021 |
url |
https://eprints.ums.edu.my/id/eprint/30036/1/Double-edged%20sword%20effect%20of%20anticoagulant%20in%20COVID-19%20infection%20FULL%20TEXT.pdf https://eprints.ums.edu.my/id/eprint/30036/2/Double-edged%20sword%20effect%20of%20anticoagulant%20in%20COVID-19%20infection%20ABSTRACT.pdf https://eprints.ums.edu.my/id/eprint/30036/ https://casereports.bmj.com/content/bmjcr/14/3/e241955.full.pdf https://doi.org/10.1136/bcr-2021- 241955 |
_version_ |
1760230710441934848 |
score |
13.160551 |